Evidence method
Level · gp.fundamentals.debt_to_revenue
113.32% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Jun 30, 2026
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration
State dimensions
Filing0001023024-26-000069General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.15% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
21.30% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
25.87% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
53.81% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.operating_margin
15.21% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
5.54% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
4.29% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 128.57%
- Current
- 113.32%
- Delta
- -15.24%
- Previous
- 2.56%
- Current
- 1.15%
- Delta
- -1.41%
- Previous
- 24.58%
- Current
- 21.30%
- Delta
- -3.28%
- Previous
- 20.46%
- Current
- 25.87%
- Delta
- 5.40%
- Previous
- 60.42%
- Current
- 53.81%
- Delta
- -6.61%
- Previous
- 16.38%
- Current
- 15.21%
- Delta
- -1.17%
- Previous
- 4.46%
- Current
- 5.54%
- Delta
- 1.08%
- Previous
- 4.29%
- Current
- 4.29%
- Delta
- -0.00%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
- Similarity
- 88%
- Compared
- 8 dimensions
- Coverage
- 100%
- Similarity
- 84%
- Compared
- 8 dimensions
- Coverage
- 100%
- Similarity
- 78%
- Compared
- 8 dimensions
- Coverage
- 100%
- Similarity
- 74%
- Compared
- 8 dimensions
- Coverage
- 100%
- Similarity
- 70%
- Compared
- 8 dimensions
- Coverage
- 100%
Research Graph
Related governed research
Analogous To · ANIP state analogue 5 →Analogous To · ANIP state analogue 4 →Analogous To · ANIP state analogue 1 →Analogous To · ANIP state analogue 2 →Analogous To · ANIP state analogue 3 →Compared To · Pharmaceutical Preparations peers →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_DECREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.